Venetoclax as a Single Agent and in Combination With PI3K-MTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15079
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Novel Chemotherapy-Free Combination Regimen for Ibrutinib-Resistant Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2017English

Copanlisib and Volasertib Overcome Ibrutinib-Venetoclax Resistance via Targeting Pi3k-Akt Signaling and G2/M Cell Cycle Transition in Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Results From the Safety Run-In Period of the Sympatico Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK Cell Effector Function in Patients With Mantle Cell Lymphoma

Haematologica
Hematology
2019English

Ibrutinib Plus Palbociclib Has Efficacy in Mantle Cell Lymphoma

Cancer Discovery
Oncology
2019English

Combination Therapy With Copanlisib and ABL Tyrosine Kinase Inhibitors Against Philadelphia Chromosome-Positive Resistant Cells

Oncotarget
Oncology
2016English

Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Mantle Cell Lymphoma With a Single Protruding Lesion as the Cause of Intussusception

Internal Medicine
Internal MedicineMedicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy